Assessment and Follow-Up of Early Undifferentiated Rheumatoid Arthritis

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Men or women - between 18 and 70 years old - affiliated with a social security scheme - who have at least 2 forms of arthritis for less than 6 weeks/months - who have not received any corticosteroids within the last 6 months (except for treatments lasting less than 2 weeks and infiltration if over 4 weeks before inclusion; except for oral steroid therapy over a period less than 2 weeks, averaging less than 20mg/day, concluded at least 15 days prior to inclusion)","clusion_E":""}